| 05th week of 2016 patent applcation highlights part 24 |
| Patent application number | Title | Published |
|---|
| 20160031853 | 2-Halo-5-Alkynyl-Pyridyl Nicotinic Ligands - Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia. | 2016-02-04 |
| 20160031854 | ACTIVATION OR REACTIVATION OF ACHE - Disclosed herein is an in vitro or in vivo method of activating or reversing inactivation of acetylcholinesterase (AChE) or butyrylcholinesterase (BuchE) using compounds of the present disclosure. Also disclosed is a method of treating a subject exposed to a nerve agent using such compounds. Also disclosed is a method of treating organophosphate poisoning in a subject using such compounds. Also disclosed is a method of modulating neuronal signaling and transmission in a subject using such compounds. | 2016-02-04 |
| 20160031855 | PROTEIN KINASE INHIBITORS - A compound of formula (I) | 2016-02-04 |
| 20160031856 | SUBSTITUTED QUINOXALINES AS FGFR KINASE INHIBITORS - The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. | 2016-02-04 |
| 20160031857 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS - The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) | 2016-02-04 |
| 20160031858 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES - The present invention relates to novel biologically active compounds, in particular dicarboxylic acid bisamide derivatives of general formula I: | 2016-02-04 |
| 20160031859 | Alkyl [(S)-1-((S)-2--buta-1,3-diynyl)-phenyl]-1H-imidazol-2-yl}-pyrrolidin- e-1-carbonyl)-2-methyl-propyl]-carbamate naphthalene-1,5-disulfonate, pharmaceutical composition, medicament, method for treatment of viral diseases - The present invention relates to NS5A inhibitors, to novel pharmaceutical composition, antiviral medicament, method for prophylaxis and treatment of viral diseases, in particular caused by hepatitis C (HCV) virus and hepatitis GBV-C virus. | 2016-02-04 |
| 20160031860 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE - The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer). | 2016-02-04 |
| 20160031861 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C - This invention relates to a compound of formula I | 2016-02-04 |
| 20160031862 | CYCLOALKYL-SUBSTITUTED PYRIMIDINEDIONE COMPOUNDS - The present invention provides novel cycloalkyl-substituted pyrimidine dione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease. | 2016-02-04 |
| 20160031863 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF - Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. | 2016-02-04 |
| 20160031864 | AROMATIC MONOMERS DERIVING FROM GLYCEROL UNITS, PROCESS FOR THEIR PREPARATION AND USE THEREOF FOR THE PREPARATION OF WATER-SOLUBLE CONJUGATED POLYMERS - Monomers having formula (I) and process for their synthesis which comprises the etherification reaction of a halogen-derivative (Z═Cl, Br, I) having formula (III) with the hydroxyl group of the glycerol derivative (IV), according to the following scheme: | 2016-02-04 |
| 20160031865 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN - Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation. | 2016-02-04 |
| 20160031866 | PYRIDIN-4-YL DERIVATIVES - The invention relates to compounds of the Formula (I), Formula (I) wherein R | 2016-02-04 |
| 20160031867 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT - The present invention provides a process for the preparation of 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-one (Aprepitant) comprising condensation of 2-(R)-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(S)-(4-fluorophenyl)morpholine hydrochloride salt with 2-(2-chloro-1-iminoethyl)hydrazinecarboxylic acid methyl ester to obtain the reaction mixture containing 2-[2-[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]-1-iminoethyl]hydrazinecarboxylic acid methyl ester, which is in-situ cyclized in the presence of dimethylsulfoxide and a polar protic solvent at a low temperature to yield aprepitant having purity ≧99.5%. | 2016-02-04 |
| 20160031868 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS - This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R | 2016-02-04 |
| 20160031869 | NOVEL INHIBITORS - The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R | 2016-02-04 |
| 20160031870 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS - Disclosed are compounds that can be used for treating tuberculosis. | 2016-02-04 |
| 20160031871 | Glycosidase Inhibitors - Compounds of formula (I) | 2016-02-04 |
| 20160031872 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS - The present invention encompasses compounds of the formula (I) | 2016-02-04 |
| 20160031873 | Carboxamide Derivatives and Use Thereof - The present disclosure provides substituted pyridyl-, pyrimidinyl-, pyrazinyl-, pyridazinyl-, and triazinyl-based carboxamides of Formula I-A: R | 2016-02-04 |
| 20160031874 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS - Disclosed are substituted aminothiazoles, which can be used for, among other things, the treatment of tuberculosis, pharmaceutical compositions containing the same, and methods of using the same. | 2016-02-04 |
| 20160031875 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS - Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc. | 2016-02-04 |
| 20160031876 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF - Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. | 2016-02-04 |
| 20160031877 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY - The invention provides kinase inhibitors of Formula I: | 2016-02-04 |
| 20160031878 | RADIOLABELED COMPOUNDS - The present invention relates to radiolabeled compounds of formula I | 2016-02-04 |
| 20160031879 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES - The present invention relates to indolizine compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders. | 2016-02-04 |
| 20160031880 | Nampt and Rock Inhibitors - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed. | 2016-02-04 |
| 20160031881 | TETRAHYDROPYRIDOPYRAZINES AS MODULATORS OF GPR6 - The present invention provides compounds of formula I: | 2016-02-04 |
| 20160031882 | IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS - This invention relates to imidazopyridyl compounds of the structural formula: | 2016-02-04 |
| 20160031883 | 2-SUBSTITUTED IMIDAZO[4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER - The present invention provides 2-substituted imidazo[4,5-d]phenanthroline compounds, which are capable of inhibiting proliferation of one or more renal cancer cells, pancreatic cancer cells, prostate cancer cells, colon cancer cells, leukemia cells, brain cancer/tumour cells or non-small cell lung cancer cells. | 2016-02-04 |
| 20160031884 | TETRAHYDROCARBOLINE DERIVATIVE - An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): | 2016-02-04 |
| 20160031885 | ORGANIC COMPOUNDS - The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT | 2016-02-04 |
| 20160031886 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein. | 2016-02-04 |
| 20160031887 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - A conjugate of formula (A): | 2016-02-04 |
| 20160031888 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER - The invention provides compounds of Formula I as inhibitors of cancer stem cells as well as cancer stem cell pathway kinase and other related kinases, pharmaceutical compositions and uses thereof in the treatment of cancer or a related disorder in a mammal, wherein i.a. R | 2016-02-04 |
| 20160031889 | ANTIVIRAL INDOLO[2,3-B]QUINOXALINE - A compound of formula (I) | 2016-02-04 |
| 20160031890 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR INHIBITION OF ROS - The present invention relates to a method using some novel compounds and compositions for the inhibition of ROS tyrosine kinase. In particular, the present invention covers a method to treat abnormal cell growth, such as cancer, with ROS | 2016-02-04 |
| 20160031891 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are amido compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2016-02-04 |
| 20160031892 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT - Compounds and compositions useful for treating disorders related to Kit are described herein. | 2016-02-04 |
| 20160031893 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME - The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and reducing the risk of microbial infections in humans and animals. | 2016-02-04 |
| 20160031894 | IMIDAZOPYRAZINE SYK INHIBITORS - Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample. | 2016-02-04 |
| 20160031895 | ORGANIC COMPOUNDS - Provided are PDE1 inhibitors of Formula I, processes for their production, their use as pharmaceuticals, and pharmaceutical compositions comprising them. | 2016-02-04 |
| 20160031896 | CRYSTAL OF 6,7-UNSATURATED-7-CARBAMOYL MORPHINAN DERIVATIVE AND METHOD FOR PRODUCING THE SAME - Stable crystalline forms of a compound represented by the formula (IA): | 2016-02-04 |
| 20160031897 | FORMS OF RIFAXIMIN AND USES THEREOF - Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them. | 2016-02-04 |
| 20160031898 | IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C - Irreversible inhibitors of K-Ras, H-Ras or N-ras protein comprising a G12C mutation are provided. Also disclosed are methods to regulate the activity of K-Ras, H-Ras or N-ras protein comprising G12C mutation and methods to disease mediated by K-Ras, H-Ras or N-ras G12C. | 2016-02-04 |
| 20160031899 | SHIP1 MODULATORS AND METHODS RELATED THERETO - Compounds of formula (II): wherein A, R | 2016-02-04 |
| 20160031900 | PROCESS FOR PREPARATION OF 3-((2S,5S)-4-METHYLENE-5-(3-OXOPROPYL)TETRAHYDROFURAN-2-YL)PROPANOL DERIVATIVES AND INTERMEDIATES USEFUL THEREOF - Discloses is a process for preparation of a compound of formula 7, or a derivative thereof, wherein PG | 2016-02-04 |
| 20160031901 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS - Described herein are compounds and chemical entities of Formula (I), methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders. | 2016-02-04 |
| 20160031902 | NOVEL MAYTANSINOID DERIVATIVES WITH SULFOXIDE LINKER - The invention relates to novel maytansinoid compounds having sulfoxide linkers and more specifically to novel maytansinoid compounds of structural formula (I) and (II). The invention also provides conjugates of the maytansinoid compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. | 2016-02-04 |
| 20160031903 | sGC STIMULATORS - Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. | 2016-02-04 |
| 20160031904 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN - Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation. | 2016-02-04 |
| 20160031905 | Macrocyclic LRRK2 Kinase Inhibitors - The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 kinase, for use in the diagnosis, prevention and/or treatment of LRRK2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent. Finally, the present invention also relates to new macrocyclic compounds. | 2016-02-04 |
| 20160031906 | Derivatized 3-Styryl-Cephalosporins - Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making betalactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections. | 2016-02-04 |
| 20160031907 | Substituted Benzene Compounds - The present invention relates to compounds of Formula (I), wherein the variables are as defined herein. Pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof are disclosed. | 2016-02-04 |
| 20160031908 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF - Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: | 2016-02-04 |
| 20160031909 | PORPHYRAZINE OPTICAL AND DUAL OPTICAL/ MR CONTRAST AND THERAPEUTIC AGENTS - Porphyrazines capable of localizing in a tumor of a mammal are disclosed. The porphyrazines are used in methods of imaging a tumor and in methods of treating tumors, either alone or in combination with a chemotherapeutic agent and/or radiation. | 2016-02-04 |
| 20160031910 | LANTHANIDE COMPLEXES COMPRISING AT LEAST TWO BETAINE GROUPS, WHICH CAN BE USED AS LUMINESCENT MARKERS - The present invention relates to luminescent lanthanide complexes including a chelating agent, formed with a macrocycle or a set of ligands, complexing a lanthanide ion Ln3+, wherein the chelating agent is substituted with at least two groups. The invention is most particularly applied to lanthanide complexes, the chelating agent of which is formed the with three ligands integrating a 2,6 pyridine-di(carboxylic acid) or is formed with a macrocycle having a 1,4,7 triazacyclononane structure. | 2016-02-04 |
| 20160031911 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS - A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein. | 2016-02-04 |
| 20160031912 | CLUSTER BORON COMPOUNDS AND USES THEREOF - The present invention relates to novel cluster boron compounds and their use as sodium channel blockers. The invention also provides methods for making and using the compounds. | 2016-02-04 |
| 20160031913 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2016-02-04 |
| 20160031914 | THERMAL CONDUCTIVE COMPOSITIONS AND METHODS FOR THEIR PREPARATION AND USE - Thermal conductive compositions, methods for their preparation, and use are provided, which include, for example, as thermal sinks and other uses. | 2016-02-04 |
| 20160031915 | HIGH REFRACTIVE INDEX SILOXANES - A polymer material comprising a constraint bicyclic bridged structure such as bicyclo(2,2,1) ring system, most preferably a norbornyl group, pendant to a siloxane backbone. The bridged bicyclic-containing materials can exhibit good refractive index, transparency, gas permeability, and/or other properties making them suitable for use in a variety of applications. | 2016-02-04 |
| 20160031916 | Substituted Silacyclopropane Precursors And Their Use For The Deposition Of Silicon-Containing Films - Provided are silacyclopropane-based compounds and methods of making the same. Also provided are methods of using said compounds in film deposition processes to deposit films comprising silicon. Certain methods comprise exposing a substrate surface to a silacyclopropane-based precursor and a co-reagent in various combinations. | 2016-02-04 |
| 20160031917 | A METHOD OF PREPARING DIALKYL-, DIARYL-, AND ALKYLARYL-DIHALOSILANES WITH HIGH SELECTIVITY IN A GRIGNARD COUPLING REACTION - A method of making a diakyl-, diaryl-, or alkylaryl-dihalosilane in a Grignard coupling reaction with a high degree of selectivity is provided. More specifically, a Grignard reagent comprising an alkyl- or aryl-magnesium halide is allowed to react with an alkyl- or aryl-trihalosilane precursor or reagent to produce a product mixture of R | 2016-02-04 |
| 20160031918 | PHOTORESPONSIVE NUCLEOTIDE ANALOGUE HAVING PHOTOCROSSLINKING ABILITY - The present invention provides a new photoreactive compound which can be used in technologies for photoreactions of nucleic acid, and also provides a photoreactive crosslinking agent comprising the above photoreactive compound. A photoreactive compound represented by the following formula I can be used. | 2016-02-04 |
| 20160031919 | SYNTHESIS AND USE OF PRECURSORS FOR ALD OF TELLURIUM AND SELENIUM THIN FILMS - Atomic layer deposition (ALD) processes for forming Te-containing thin films, such as Sb—Te, Ge—Te, Ge—Sb—Te, Bi—Te, and Zn—Te thin films are provided. ALD processes are also provided for forming Se-containing thin films, such as Sb—Se, Ge—Se, Ge—Sb—Se, Bi—Se, and Zn—Se thin films are also provided. Te and Se precursors of the formula (Te,Se)(SiR | 2016-02-04 |
| 20160031920 | METAL ORGANIC FRAMEWORK MATERIALS - An imidazolate framework material comprises a general structure, M | 2016-02-04 |
| 20160031921 | OXYGEN ASSISTED ORGANOSOLV PROCESS, SYSTEM AND METHOD FOR DELIGNIFICATION OF LIGNOCELLULOSIC MATERIALS AND LIGNIN RECOVERY - An oxygen assisted Organosolv process for a more efficient delignification and producing bio-products by decomposing lignocellulosic materials comprises providing a lignin solvent with water, an acid, an oxidant and one or more lignin dissolving chemicals. The process also includes placing biomass in contact with oxidant, acid, water, the lignin solvent in any order or combined to form a recyclable solvent, and recycling at least a portion of the recyclable solvent by circulating the recyclable solvent back into contact with the biomass. The circulating of the recyclable solvent occurs for a period of time, during which, acid and oxidant may be added if necessary as they may be consumed by the process, after which, the process then includes separating material such as chemicals and lignin from the recyclable solvent. The chemicals can be recycled as new lignin dissolving solvent or sold, while lignin can be used as natural and renewable colorant for polymers such as poly lactic acid, or mixed with other polymers as an additive and extruded or injected to consumable polymeric parts, or can be used and the natural source of renewable aromatics. Application of an oxidant will help the overall fractionation process by changing the chemical characteristics of the lignin and therefore allows more lignin to be removed from biomass. At the end, the lignin is separated from the lignin dissolving solvent by a separation process to also reclaim the lignin dissolving solvent for the next fractionation process. | 2016-02-04 |
| 20160031922 | NUCLEIC ACID PURIFICATION - Methods and composition for nucleic acid isolation are provided. In one embodiment, the invention provides a method for nucleic acid purification from biological samples extracted with phenol-based denaturing solvents, which does not require phase separation or nucleic acid precipitation. Methods according to the invention may also be used for differential isolation of RNA and DNA. | 2016-02-04 |
| 20160031923 | GLYCOSIDE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS PROSTHETIC GROUPS - The present invention relates to glycoside-derived compounds, to the processes for preparing same and to the use thereof as prosthetic groups for radiolabelling biomolecules. These compounds are co-azido-alkyl 6-deoxy-6-[ | 2016-02-04 |
| 20160031924 | METHODS FOR PURIFYING STEVIOL GLYCOSIDES AND USES OF THE SAME - Methods for purifying steviol glycosides, including Rebaudioside X, are provided herein. Sweetener and sweetened containing Rebaudioside X are also provided herein. Methods of improving the flavor and/or temporal profile of sweetenable compositions, such as beverages, are also provided. | 2016-02-04 |
| 20160031925 | AZITHROMYCIN ANTIMICROBIAL DERIVATIVES WITH NON-ANTIBIOTIC PHARMACEUTICAL EFFECT - The invention provides molecules, which are based on a modification of azithromycin, removing the antibiotic effect, while retaining other beneficial effects, such as, but not limited to immunomodulatory effects. The compounds of the invention can be described by compounds of Formula (I) as further defined herein. | 2016-02-04 |
| 20160031926 | Triazole Compounds and Methods of Making and Using the Same - The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. | 2016-02-04 |
| 20160031927 | Alkyl 2--propionates, nucleoside inhibitors of HCV RNA-polymerase NS5B, methods for preparation and use thereof - Compounds of the general formula 1, stereoisomers, pharmaceutically acceptable salts, and/or hydrates, solvates or crystalline forms thereof | 2016-02-04 |
| 20160031928 | RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS - Disclosed are messenger RNA molecules and related compositions incorporating a 4′-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders. In certain embodiments, the 4′-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies. | 2016-02-04 |
| 20160031929 | INHIBITORS OF CYP17A1 - Compounds according to formula I or II are provided. Such compounds are useful in treating cancers, such as leukemia, colon cancer, breast cancer, or prostate cancer by beneficially inhibiting CYP17A1. Pharmaceutical compositions and methods including the compounds are also provided. | 2016-02-04 |
| 20160031930 | NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF - (3alpha,3beta)-disubstituted 17beta steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions. | 2016-02-04 |
| 20160031931 | SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS - Systems and processes for performing solid phase peptide synthesis are generally described. Solid phase peptide synthesis is a known process in which amino acid residues are added to peptides that have been immobilized on a solid support. In certain embodiments, the inventive systems and methods can be used to perform solid phase peptide synthesis quickly while maintaining high yields. Certain embodiments relate to processes and systems that may be used to heat, transport, and/or mix reagents in ways that reduce the amount of time required to perform solid phase peptide synthesis. | 2016-02-04 |
| 20160031932 | REFOLDING OF PROTEINS - Provided is a method of refolding of recombinant GCSF that minimizes the generation of oxidized forms of GCSF by optimizing the refolding of inclusion bodies containing recombinant GCSF. | 2016-02-04 |
| 20160031933 | AMINO ACIDS PRODUCED ACCORDING TO A PROCESS OF MECHANOCATALYTIC HYDROLYSIS OF PROTEINS - The presently disclosed and/or claimed inventive concept(s) relates generally to processes for the non-aqueous hydrolysis of proteins and/or protein-containing materials and, more particularly but without limitation, to methods for producing amino acids from the non-aqueous solid acid hydrolysis of proteins and/or protein-containing materials. More particularly, but without limitation, the methods disclosed herein for producing amino acids from the solid acid hydrolysis of proteins and/or protein-containing materials are performed in a non-aqueous/solvent-free process. In one particular embodiment, the process of producing such amino acids from proteins and/or protein-containing materials includes, without limitation, the step of mechanocatalytically reacting a solid acid with one or more proteins and/or protein containing materials in a non-aqueous/solvent-free process using the solid acid as a catalyst. | 2016-02-04 |
| 20160031934 | DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS - Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases. | 2016-02-04 |
| 20160031935 | SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF - A compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or racemic mixture or stereoisomer thereof, and methods for preventing or treating an LDL-cholesterol-related disease or disorder using such compound(s), and kits and compositions comprising such compound(s). | 2016-02-04 |
| 20160031936 | TRIAZOLE MACROCYCLE SYSTEMS - The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production. | 2016-02-04 |
| 20160031937 | NEURAL REGENERATION PEPTIDES AND USES THEREFOR - This invention relates to neural regeneration peptides (NRPs), including NRP-2945, NRP-2983 and NNZ-4921, as well as the receptors that have been newly identified as interacting with these NRPs, such as CXCR4 in collaboration with CCR3. The invention further relates to methods of using these NRPs and its respective chemokine receptors, as well as compositions comprising such components. | 2016-02-04 |
| 20160031938 | PEPTIDE SELECTIVELY BINDING TO GRAPHITIC MATERIALS AND VOLATILE ORGANIC COMPOUNDS - Provided is a peptide including X | 2016-02-04 |
| 20160031939 | MODIFICATION OF POLYPEPTIDES - The invention provides a method for conjugating a peptide displayed on a genetic display system to a molecular scaffold performed on an ion exchange resin. | 2016-02-04 |
| 20160031940 | WATER BUFFALO DERIVED PEPTIDE ANTIBIOTIC THERAPIES - The present disclosure relates to antimicrobial agents and methods of using such agents. The disclosure includes antimicrobial agents having broad spectrum antimicrobial activity, nucleic acids and amino acid sequences encoding such antimicrobial agents, as well as methods of using the antimicrobial agents. The antimicrobial agents of the disclosure may be used to reduce survival of a microbe, as an antimicrobial therapeutic, in microbial treatment protocols, and in research, as well as other uses related to reducing microbe survival. In addition, the disclosure also includes compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial agent. | 2016-02-04 |
| 20160031941 | TARGETING PEPTIDES THAT BIND S. MUTANS, CONSTRUCTS COMPRISING SUCH PEPTIDES AND USES THEREOF - In certain embodiments, novel targeting peptides that specifically/preferentially bind to | 2016-02-04 |
| 20160031942 | RHAMM BINDING PEPTIDES - The present invention provides for peptides that bind to Receptor for Hyaluronic Acid Mediated Motility (RHAMM) molecules. More specifically, provided are peptides capable of specifically binding RHAMM molecules and capable of binding RHAMM with substantially high affinity. These novel RHAMM-binding peptides provide the basis for new imaging probes that can be used to identify cells expressing RHAMM, and for methods of imaging, prognosis, diagnosis and treatment of conditions associated with RHAMM expression. | 2016-02-04 |
| 20160031943 | COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS - The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein —Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that —three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and —the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus. | 2016-02-04 |
| 20160031944 | a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS - The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of α4β7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo. | 2016-02-04 |
| 20160031945 | MATERIALS AND METHOD FOR SUPPRESSING INFLAMMATORY AND NEUROPATHIC PAIN - N-type voltage-gated calcium channels (CaV2.2) are critical mediators of neurotransmitter release and are thought to be involved with transmission of nociception. The use of conventional CaV2.2 blockers in pain therapeutics is limited by side effects. Reported herein is a means to suppress both inflammatory and neuropathic pain without directly blocking CaV2.2, but rather by inhibiting the binding of the axonal collapsin response mediator protein 2 (CRMP-2), a protein known to enhance CaV2.2 function. A 15 amino acid peptide of CRMP-2 fused to the protein transduction domain of the HIV tat protein (TAT CBD3) reduced meningeal blood flow induced by activation of the trigeminovascular system, prevented inflammation-induced tactile hypernociception induced by intraplantar formalin and nocifensive behavior following corneal capsaicin application, and reversed neuropathic hypernociception produced by the antiretroviral drug 2′,3′-dideoxycytidine. Preventing CRMP-2-mediated enhancement of CaV2.2 function suppressed inflammatory and neuropathic nociception, providing a method for treating pain and inflammation. | 2016-02-04 |
| 20160031946 | MULTI-EPITOPIC VACCINE - The present invention relates to isolated polypeptides comprising: (i) a protein transduction domain consisting of ZEBRA or a fragment thereof that retains the capacity of internalization, (ii) at least one CD4 | 2016-02-04 |
| 20160031947 | CUPREDOXIN DERIVED TRANSPORT AGENTS AND METHODS OF USE THEREOF - The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer. | 2016-02-04 |
| 20160031948 | FUSION PROTEINS AND METHODS FOR STIMULATING PLANT GROWTH, PROTECTING PLANTS, AND IMMOBILIZING BACILLUS SPORES ON PLANTS - The present invention is generally directed to fusion proteins containing a targeting sequence that targets the fusion protein to the exosporium of a | 2016-02-04 |
| 20160031949 | NOVEL INSECTICIDAL PROTEINS AND METHODS OF USE - Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are isolated insecticidal proteins and nucleic acids. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest, as probes for the isolation of other homologous (or partially homologous) genes. The insecticidal proteins find use in controlling or killing lepidopteran, coleopteran, dipteran, fungal, hemipteran, and nematode pest populations and for producing compositions with insecticidal activity. | 2016-02-04 |
| 20160031950 | Method for Protein Extraction from Oil Seed - The present invention relates to the selective extraction of proteins over oil from oil seed meal, preferably from cold pressed oilseed meal, for the purpose of producing protein isolates composed of native proteins. More specifically, the invention describes a method for producing from oil seed meal an intermediate aqueous protein solution having a fat to protein ratio of at least 1:12 comprising subjecting oil seed meal to aqueous extraction under minimal shear conditions and optionally collecting the resulting intermediate aqueous protein solution. | 2016-02-04 |
| 20160031951 | PEPTIDES HAVING REDUCED TOXICITY THAT STIMULATE CHOLESTEROL EFFLUX - The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia. | 2016-02-04 |
| 20160031952 | Amyloidosis-inhibiting Polypeptides and Their Use - Isolated polypeptides that possess an a-sheet structure are disclosed that can be used to treat or diagnose amyloid diseases. | 2016-02-04 |
